May 15, 2017 07:45 AM EDT

Ionis says it gathered promising PhIII data for a top rare disease drug, but serious safety questions remain

John Carroll

Editor & Founder

Ionis Pharmaceuticals $IONS says that its Phase III study of inotersen (IONIS-TTRRx) hit both primary endpoints in patients with rare cases of familial amyloid polyneuropathy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ionis says it gathered promising PhIII data for a top rare disease drug, but serious safety questions remain

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

WuXi companies may sell units impacted by Biosecure — report

Biotech's third quarter was relatively bright — with a few caveats

Sanofi sells rare disease drug Enjaymo to Recordati for $825M upfront

RSV vaccines off to a sluggish start in US this season, with volumes behind 2023

EMA reviews hair loss products following concerns about suicidal thoughts

3 Tiers for AAV Potency Assay Development Success

Io­n­is says it gath­ered promis­ing PhI­II da­ta for a top rare dis­ease drug, but se­ri­ous safe­ty ques­tions re­main

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Ionis says it gathered promising PhIII data for a top rare disease drug, but serious safety questions remain